Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 31, 2011. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 1,100,000 Ordinary shares of 25 pence each.
- Purchase Date: May 31, 2011.
- Price Range: Highest price paid was 1,324 pence per share; lowest price paid was 1,308.5 pence per share.
- Treasury Holdings (Settled): 496,724,284 shares (8.78% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,174,284 shares (9.67% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,160,098,367 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 1,100,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 9.67% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share ownership and repurchase execution.
Investor Verification Checklist
- Verify the total number of shares in issue (5,160,098,367) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the settlement status of the 1,100,000 shares purchased on May 31, 2011.
- Review the total Treasury share count (499,174,284) to assess the impact on voting rights (9.67%).